In another interview from ASH 2013 that I just posted on my blog bkoffman.blogspot.com , Dr. John Pagel out of the Hutch and I discuss the role and the politics of the underuse of radioimmune therapy in CLL.
It is worth listening to just to hear his clever analogy of how the drugs work.
I believe that (they) have an under realized role as a mop up or consolidation therapy after the disease burden has been reduced. This is the model that has been successfully deployed in other lymphomas, but not in CLL.
More interviews to come from ASH as I get ready for ASCO 2014.
If you haven't already, please check out Dr. Sharman's latest post on his crazy schedule at the upcoming ASCO cll-nhl.com . We are planning to connect there for a quick interview, but finding a mutual time that works could be tough.
It is just great that we have so much research data to report on.
Admin: Removed brackets around web links so they will work. Added missing 'they' referring to aforementioned radioimmune therapy drugs.